Skip to content
← The Index board

Experimental · 5.1/10

Survodutide (BI 456906)

Evidence C · mixed evidence ▲ 14.6% momentum 🥇 First scout open
5.1/ 10

Survodutide (BI 456906) is an investigational once-weekly GLP-1 and glucagon dual agonist that drove up to 16.6% weight loss in Phase 3, per the Boehringer Ingelheim SYNCHRONIZE-1 topline, and 62% liver-disease improvement on its best Phase 2 dose, per Sanyal 2024. Read the full breakdown →

The prediction game

Where does Survodutide (BI 456906) go in 12 months?

Lock a call and say how sure you are. Right and confident earns the most; a leaderboard spot is the prize. No money, no stakes.

The Crowd’s Call

Rising or fading over the next 12 months? Lock your call and find out if you saw it coming.

Your 12-month call on Survodutide (BI 456906)

New voice here? We send a one-tap verification link so every entry comes from a real person. Signed-in members skip this.

Be the first scout on record for Survodutide (BI 456906). Permanent credit on this page, plus points when your call resolves.

One call per intervention. It locks the moment you submit (no edits, no cancels) and resolves in 12 months. See the scout leaderboard →

Weigh In

Your input feeds the community signal shown beside my verdict. It informs the board and it never sets the score by itself. How community input works.

Tried it in real life?

Which ring does it deserve?

Same as above — one verification covers all your entries here.

Ring Experimental Momentum 14.6% Updated Jul 20, 2026 How the Index ranks →

Verdict by Nick Urban, host of the High Performance Longevity podcast.

For education only, not medical advice. Supplements, peptides, and protocols can interact with medications and conditions. Talk to a qualified clinician before starting anything here.